KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.96

Relationship of radiographic progression status to low disease activity in patients with PsA receiving secukinumab treatment for 2 years.

Philip J Mease, Laura C Coates, Corine Gaillez, Alexis Shew, Weibin Bao, Christopher T Ritchlin

Rheumatology (Oxford) 65(1) keaf488

PMID40973471
PMCIDPMC12862373
DOI10.1093/rheumatology/keaf488
发表日期2025-09-19
入排依据:属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 5 张 PMC Figure,均未识别为 KM 图:Figure 1.:AI 判定为 flow diagram;Figure 2.:非 KM 图;Figure 3.:非 KM 图;Figure 4.:AI 判定为 other;Figure 5.:非 KM 图。
摘要

摘要

OBJECTIVE: To examine relationships between radiographic progression and achievement of low disease activity (LDA) or remission at week 104 in patients with PsA receiving secukinumab. METHODS: This post hoc analysis included data from patients with active PsA enrolled in the phase 3 FUTURE 5 study (NCT02404350). Patients were pooled by treatment received at week 104 (secukinumab 300 mg with loading dose [LD], secukinumab 150 mg with LD or secukinumab 150 mg without LD) and grouped by radiographic progression status. Radiographic progression was defined as change from baseline to week 104 in van der Heijde modified Total Sharp Score >0.5. Efficacy was assessed by achievement of minimal disease activity (MDA), very low disease activity (VLDA) and Disease Activity Index for PsA (DAPSA) LDA or remission. Demographics and clinical characteristics associated with radiographic progression at week 104 were identified by logistic regression analyses. RESULTS: Of the 541 patients included in this analysis, 457 (84.5%) were radiographic non-progressors and 84 (15.5%) were radiographic progressors. Higher proportions of non-progressors achieved MDA, VLDA and DAPSA LDA and remission at week 104 than progressors. Radiographic progression at week 104 was associated with older age and higher baseline high-sensitivity CRP level, whereas non-progression was associated with 300 mg secukinumab (vs 150 mg secukinumab without LD), no prior exposure to tumour necrosis factor inhibitors and lower BMI. CONCLUSION: Patients without radiographic progression through 2 years of secukinumab treatment had greater achievement of LDA states at week 104 than patients with radiographic progression. TRIAL REGISTRATION: ClinicalTrials.gov; NCT02404350.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(5,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1.Distribution of patients with or without radiographic progression at week 104 by treatment group. NL, no loading dose; vdH-mTSS, van der Heijde modified Total Sharp Score
非 KM Figure
Figure 2.Achievement of LDA states a at week 104 grouped by radiographic progression status at week 104. Outcomes are summarized descriptively using observed data. DAPSA, Disease Activity Index for PsA; LDA, low disease activity; MDA, minimal disease activity; NL, no loading dose; SEC, secukinumab; VAS, visual analogue scale; VLDA, very low disease activity. a The criteria for DAPSA LDA, DAPSA remission, MDA and VLDA are defined in the Methods section
非 KM Figure
Figure 3.Proportions of patients who achieved SJC66 ≤1, TJC68 ≤1 and ≤1 tender entheseal point at week 104 grouped by radiographic progression status at week 104. Outcomes are summarized descriptively using observed data. NL, no loading dose; SEC, secukinumab; SJC66, swollen joint count in 66 joints; TJC68, tender joint count in 68 joints
非 KM Figure
Figure 4.Proportions of patients who achieved HAQ-DI score ≤0.5, PtGA VAS score ≤20, patient pain VAS score ≤15 and PASI score ≤1 or ≤3% BSA affected at week 104 grouped by radiographic progression status at week 104. Outcomes are summarized descriptively using observed data. BSA, body surface area; HAQ-DI, Health Assessment Questionnaire Disability Index; NL, no loading dose; PASI, Psoriasis Area and Severity Index; PtGA, Patient’s Global Assessment of disease activity; SEC, secukinumab; VAS, visual analogue scale
非 KM Figure
Figure 5.Baseline and week 16 patient characteristics associated with radiographic progression status at week 104. a Logistic regression analyses were used to determine demographics and clinical characteristics (at baseline and week 16) associated with radiographic progression status at week 104. hsCRP, high-sensitivity CRP; NL, no loading dose; SEC, secukinumab; TNFi, tumour necrosis factor inhibitor; vdH-mTSS, van der Heijde modified Total Sharp Score. a Change from baseline in vdH-mTSS of ≤0.5 (non-progression) vs >0.5 (progression)
非 KM Figure